News | January 28, 2014

Bard’s Drug Coated Balloon, Below the Knee Clinical Trial Discussed at Leipzig Interventional Course

Bard Drug Coated Balloon Below the Knee Clinical Trial Peripheral Artery Disease

January 30, 2014 — Experts presented six-month LEVANT 2 trial results for C. R. Bard Inc.’s Lutonix drug coated balloon (DCB) and provided updates on the ongoing Lutonix Below the Knee (BTK) Clinical Trial at the Leipzig Interventional Course (LINC) in Leipzig, Germany.
 
The symposium took place Jan. 29. 
 
LEVANT 2 study design — Professor Dierk Scheinert, M.D., head of the Department of Medicine, Angiology and Cardiology, Park-Krankenhaus Hospital, Leipzig, Germany
Single center experience global SFA registry — Michael Lichtenberg, M.D., Klinikum Arnsberg, Arnsberg, Germany
BTK applications and Lutonix BTK Clinical Trial — Professor Marianne Brodmann, M.D., associate professor and assistant medical director, Division of Angiology, Medical University Graz, Austria
Techniques in complex BTK cases — Francesco Liistro, M.D., San Donato Hospital, Arezzo, Italy
Pre-clinical safety data and technology review — Renu Virmani, M.D., CVPath Institute, Gaithersburg, Maryland, United States
A single center experience with Lutonix — Peter Baron von Bilderling, M.D., Gefäßpraxis im Tal, Munich, Germany
 
Bard announced in June 2013 enrollment of the first patient in the Lutonix BTK Clinical Trial. The global and multi-center, randomized Investigational Device Exemption (IDE) trial is ongoing and is intended to compare the safety and effectiveness of the Lutonix 014 Drug Coated PTA Dilatation Catheter to a standard angioplasty balloon for the treatment of CLI. The trial is expected to enroll several hundred patients at 55 sites worldwide.
 
For more information: www.crbard.com

Related Content

News | Peripheral Artery Disease (PAD)

January 17, 2022 – The Vascular Care Group (TVCG) announced Stephen J. Hoenig M.D., successfully completed a ...

Home January 17, 2022
Home
News | Peripheral Artery Disease (PAD)

October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...

Home October 20, 2021
Home
News | Peripheral Artery Disease (PAD)

June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...

Home June 07, 2021
Home
News | Peripheral Artery Disease (PAD)

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

Home May 17, 2021
Home
News | Peripheral Artery Disease (PAD)

January 26, 2021 — Pedra Technology, a privately held company, announced today that the U.S. Food and Drug ...

Home January 26, 2021
Home
News | Peripheral Artery Disease (PAD)

November 13, 2020 — The new U.S. Food and Drug Administration (FDA) cleared XO Score system was successfully used to ...

Home November 13, 2020
Home
News | Peripheral Artery Disease (PAD)

September 4, 2020 — The U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment ...

Home September 04, 2020
Home
News | Peripheral Artery Disease (PAD)

June 16, 2020 — The 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent ...

Home June 16, 2020
Home
News | Peripheral Artery Disease (PAD)

March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with ...

Home March 28, 2020
Home
News | Peripheral Artery Disease (PAD)

November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical ...

Home November 14, 2019
Home
Subscribe Now